Aegirbio is conducting a fully guaranteed rights issue of units to private and institutional investors in Sweden. Full subscription to the issue will raise approximately SEK 15 million before costs. In the event of high demand, the board of directors has the opportunity to allocate additional units equivalent to up to SEK 2.25 million before the deduction of issue costs. Should the issue be fully subscribed and all TO1 warrants are exercised within the scope of the offer and any additional allotment, the company may raise an additional SEK 20.7 million before the deduction of issue costs.
Aegirbio intends to apply to have the company’s shares and warrants listed on the Nasdaq First North Growth Market. The registration period for participating in the offer is 1-15 June 2020, with the provisional first day of trading set for 26 June 2020.
The purpose of the offer is to finance the continued development of Aegirbio into a market-driven company, initially through the continued commercialisation of its product MoNATor. MoNATor is a dose-monitoring laboratory developed test (LDT) designed for the US market, initially commercialised for use with biomedicine Natalizumab (Tysabri) in the treatment of multiple sclerosis.
Lindahl has provided Aegirbio with legal counsel in conjunction with the issue through a team consisting of Monica Lagercrantz and Dennis Westermark (responsible partners), Ola Svanberg, Nicklas Bexelius and Lisa Liljekvist. Eminova Partners AB has provided financial advice in conjunction with the issue.
